Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.
Zhang Y, Martin SW, Rose CE Jr, Biagini RE, Franzke LH, Smith JP, Sammons DL, Robertson SA, McNeil MM. Zhang Y, et al. Among authors: martin sw. Pharmacoepidemiol Drug Saf. 2008 Nov;17(11):1060-7. doi: 10.1002/pds.1657. Pharmacoepidemiol Drug Saf. 2008. PMID: 18781705
Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.
Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM; Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program. Tierney BC, et al. Among authors: martin sw. Clin Infect Dis. 2003 Oct 1;37(7):905-11. doi: 10.1086/377738. Epub 2003 Sep 12. Clin Infect Dis. 2003. PMID: 13130401
Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.
Pondo T, Rose CE Jr, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker S, Jacobson RM, Poland GA, McNeil MM. Pondo T, et al. Among authors: martin sw. Vaccine. 2014 Jun 12;32(28):3548-54. doi: 10.1016/j.vaccine.2014.04.025. Epub 2014 Apr 24. Vaccine. 2014. PMID: 24768633 Free PMC article. Clinical Trial.
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.
Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP; Anthrax Vaccine Research Program Working Group. Marano N, et al. Among authors: martin sk, martin sw. JAMA. 2008 Oct 1;300(13):1532-43. doi: 10.1001/jama.300.13.1532. JAMA. 2008. PMID: 18827210 Clinical Trial.
Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial.
Stewart B, Rose CE, Tokars JI, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker SD, Jacobson RM, Poland GA, McNeil MM. Stewart B, et al. Among authors: martin sw. Vaccine. 2012 Aug 31;30(40):5875-9. doi: 10.1016/j.vaccine.2012.06.076. Epub 2012 Jul 17. Vaccine. 2012. PMID: 22814409 Free PMC article. Clinical Trial.
Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.
Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP. Wright JG, et al. Among authors: martin sk, martin sw. Vaccine. 2014 Feb 12;32(8):1019-28. doi: 10.1016/j.vaccine.2013.10.039. Epub 2013 Dec 25. Vaccine. 2014. PMID: 24373307 Free PMC article. Clinical Trial.
441 results